Free Helpline
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
We are here to assist you.
Health Advisor
+91-8877772277Available 7 days a week
10:00 AM – 6:00 PM to support you with urgent concerns and guide you toward the right care.
Explore Uplizna dosage for NMOSD. This guide covers standard administration, side effects, precautions, and how this medication helps manage Neuromyelitis Optica Spectrum Disorder, including symptoms, diagnosis, and what to expect during treatment. Learn about missed doses, important warnings, and when to consult your doctor.
Confused about whether CBD can get you high? Understand the difference between CBD and THC, their effects on your body, and what to look for in safe, non-intoxicating CBD products.
April 1, 2026
Learn about anticoagulants and antiplatelet drugs, often called blood thinners. Understand how they prevent blood clots, when they're prescribed, their side effects, and essential safety tips for Indian readers.
April 1, 2026
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare, debilitating autoimmune disease that primarily affects the optic nerves and spinal cord. It can lead to severe vision loss, paralysis, and even death. For individuals living with NMOSD, effective treatment is crucial to prevent relapses and minimize disease progression. One such treatment is Uplizna (inebilizumab), an intravenous medication designed to reduce the frequency of NMOSD attacks.
Understanding the correct dosage, administration, and potential considerations associated with Uplizna is paramount for both patients and healthcare providers. This comprehensive guide will delve into the specifics of Uplizna dosage, its mechanism of action, potential side effects, and other vital information to help you manage your NMOSD effectively.
Before we discuss Uplizna, it's important to understand the condition it treats. NMOSD is a chronic inflammatory disorder of the central nervous system (CNS). It was historically considered a variant of multiple sclerosis (MS) but is now recognized as a distinct condition with different pathological mechanisms and treatment approaches.
NMOSD attacks can be severe and often lead to permanent disability. Symptoms vary depending on which parts of the CNS are affected, but commonly include:
These attacks are typically severe and can result in significant residual disability.
NMOSD is an autoimmune disease, meaning the body's immune system mistakenly attacks its own healthy tissues. In most cases (about 70-80%), NMOSD is associated with the presence of an antibody called aquaporin-4 immunoglobulin G (AQP4-IgG).
AQP4 is a protein found on the surface of astrocytes, which are star-shaped support cells in the brain and spinal cord. The AQP4-IgG antibody targets and damages these astrocytes, leading to inflammation and demyelination (damage to the protective covering of nerve fibers) in the optic nerves, spinal cord, and sometimes the brain.
While the exact trigger for the immune system to produce these antibodies is unknown, it is believed to involve a combination of genetic predisposition and environmental factors.
Diagnosing NMOSD involves a combination of clinical evaluation, imaging, and laboratory tests:
Uplizna (inebilizumab) is a monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with NMOSD who are AQP4-IgG seropositive. It works by targeting CD19-expressing B cells, including plasmablasts and plasma cells, which are believed to play a critical role in the pathogenesis of NMOSD by producing the harmful AQP4-IgG antibodies.
Uplizna binds to CD19, a protein found on the surface of B cells. By binding to CD19, Uplizna causes the depletion of these B cells from circulation. This reduction in B cells leads to a decrease in the production of pathogenic antibodies, including AQP4-IgG, thereby reducing inflammation and the frequency of NMOSD attacks.
Proper dosage and administration are essential for Uplizna to be effective and to minimize the risk of side effects. Uplizna is administered as an intravenous (IV) infusion by a healthcare professional.
The recommended dosage of Uplizna for adult patients with AQP4-IgG seropositive NMOSD is as follows:
It is crucial to adhere strictly to this dosing schedule to maintain therapeutic levels of the medication and prevent relapses.
Uplizna is administered intravenously, meaning it is delivered directly into a vein. The infusion process requires careful attention:
Uplizna is not intended for self-administration and should always be given by a trained healthcare professional in a clinical setting equipped to manage potential infusion reactions.
If a dose of Uplizna is missed, it should be administered as soon as possible. The next dose should then be scheduled 6 months from the date of the last administration. It is important to inform your healthcare provider immediately if you miss a dose so they can adjust your schedule accordingly.
There is limited clinical experience with Uplizna overdose. In the event of an overdose, patients should be closely monitored for signs or symptoms of adverse reactions and appropriate symptomatic treatment should be initiated. There is no specific antidote for Uplizna.
Like all medications, Uplizna can cause side effects. It's important to be aware of these and discuss any concerns with your healthcare provider.
The most common side effects reported in clinical trials (occurring in at least 10% of patients) include:
These side effects are generally mild to moderate and often manageable.
More serious side effects, though less common, can occur and require immediate medical attention:
Always report any new or worsening symptoms to your doctor promptly.
Several important warnings and precautions are associated with Uplizna use:
Uplizna is an immunosuppressant. Therefore, caution is advised when co-administering Uplizna with other immunosuppressive therapies or treatments that affect immune function. The safety and efficacy of Uplizna in combination with other NMOSD therapies have not been fully established. Discuss all medications, supplements, and herbal remedies you are taking with your doctor to avoid potential interactions.
The safety and effectiveness of Uplizna in pediatric patients have not been established.
Clinical studies of Uplizna did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. However, no overall differences in safety or effectiveness were observed between older and younger subjects in clinical trials.
No specific dose adjustments are recommended for patients with renal or hepatic impairment, as Uplizna is a large protein and is not primarily cleared by renal or hepatic pathways.
It is important to maintain regular communication with your healthcare provider while on Uplizna. You should contact your doctor immediately if you experience any of the following:
Regular follow-up appointments and blood tests (e.g., to monitor immunoglobulin levels) are crucial to ensure the safety and effectiveness of your treatment.
Uplizna is administered as an intravenous (IV) infusion by a healthcare professional in a clinical setting. It is not self-administered.
Each 300 mg infusion typically takes a minimum of 90 minutes. You will also need time for pre-medication and post-infusion monitoring.
If you miss a dose, contact your healthcare provider immediately. They will advise you on when to receive the missed dose and adjust your subsequent dosing schedule accordingly. It's important not to delay treatment.
Uplizna is a treatment that helps reduce the frequency of NMOSD relapses and can slow disease progression. It is not a cure for NMOSD, as NMOSD is a chronic condition.
Serious side effects can include severe infusion reactions, serious infections (such as urinary tract infections, upper respiratory infections, and rarely, progressive multifocal leukoencephalopathy or PML), and decreased immunoglobulin levels. Your doctor will monitor you for these risks.
Live-attenuated or live vaccines should not be administered during Uplizna treatment and until B-cell repletion. Discuss any vaccination plans with your healthcare provider.
After the initial two doses (given 2 weeks apart), maintenance doses are administered every 6 months.
Uplizna (inebilizumab) represents a significant advancement in the management of AQP4-IgG seropositive Neuromyelitis Optica Spectrum Disorder. By targeting CD19-expressing B cells, it helps to reduce the frequency of debilitating NMOSD attacks, offering hope for improved quality of life for patients.
Adhering to the prescribed dosage regimen, understanding the administration process, and being aware of potential side effects and precautions are critical for successful treatment. Always maintain open communication with your healthcare team, report any concerns promptly, and follow all medical advice to ensure the safest and most effective use of Uplizna in your NMOSD management plan.
Confused about Plan B and abortion pills? Understand the key differences, how they work, and their effectiveness for informed reproductive health decisions.
April 1, 2026